BioCentury – Decelerating the hyperbole over accelerated approval
In the increasing controversy surrounding FDA’s accelerated approval pathway, it’s far too easy to overlook why this pathway exists in the first place — to define a medicine’s value through its clinical utility, while striking a regulatory balance between quality, speed and value. The key “red thread” behind much of this manufactured controversy is the prioritization of…